General Information

Australia’s R&D Tax Incentive and Clinical Sector To Be Showcased During JP Morgan Week

December 7th, 2020

AusBiotech’s virtual showcase during JP Morgan week in January 2021 will seek to highlight the advantages of partnering with Australian life science companies and utilising the R&D Tax Incentive. Australia has become an attractive location for the conduct of clinical trials in recent years, based on local capability and infrastructure offering companies the ability to attain high-quality clinical data. Australia’s 43.5% Refundable R&D Tax Offset has further made the country an attractive destination for the conduct of clinical research. Ausbiotech’s […]

Read More

Independent Review of TPB Makes Reference to R&D Tax Practitioners

November 30th, 2020

Regulation of the tax profession is the responsibility of the Tax Practitioners Board (TPB) which was formed following the Tax Agent Services Act 2009 (TASA)’s introduction. An independent review into the effectiveness of the TPB has been undertaken over recent years, and this week the final review report has been released, following earlier consultations and publications of a discussion paper. Within the final report, reference is made to Tax intermediaries: of which R&D Tax Advisors are specifically named. The review report […]

Read More

AusIndustry Publish Redrafted Guide to Interpretation Document

November 9th, 2020

AusIndustry’s original Guide to Interpretation was published in January 2016, and has been considered the primary document for detailing how AusIndustry interprets key elements of the definition of ‘R&D activities’ as defined in the legislation. Material from the Guide to Interpretation was often referred to be AusIndustry during compliance processes, and it detailed AusIndustry’s position on complex issues, such as: Assessment of the purpose for which R&D Activities were undertaken; The scope of activities that are specifically excluded from consideration as Core […]

Read More

Opposition Comments on Government’s Revised R&D Tax Reforms Passed From the Federal Budget

October 26th, 2020

When the federal government announced in December 2019 that they would reintroduce their previous R&D Tax Reform bill with a proposed start date of July 2019 for FY20, it was met with widespread condemnation from industry leaders. The bill reintroduced at that time was largely focused on savings measures, and was a slightly modified version of a previous reform bill, which did not pass through the Senate. The Senate Economics Committee had noted concerns around the proposed intensity threshold and […]

Read More

Categories

Archives

    Email this job